# OnCo record rationale-302 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/rationale-302/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "rationale-302", "NCT03430843" ;
  schema:name "RATIONALE-302"@en ;
  schema:description "The global trial in which tislelizumab beat chemotherapy for oesophageal cancer that had progressed after first treatment, which carried it to approval in the US, Europe and Japan."@en ;
  schema:url <https://onco.cc/trials/rationale-302/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT03430843>, <https://doi.org/10.1200/JCO.21.01926> ;
  onco:status "positive" ;
  onco:tag "china" ;
  onco:phase "3" ;
  schema:startDate "2018-01-26" ;
  onco:cancers <https://onco.cc/cancers/esophageal/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:drugs <https://onco.cc/drugs/tislelizumab/> ;
  onco:companies <https://onco.cc/companies/beone/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-shen-j-clin-oncol/> .